Effect of coagulation-regulation system by heme-oxygenase 1 on improvement of pregnancy outcome.

2014 Fiscal Year Final Research Report

• Project/Area Number: 24790549
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Laboratory medicine
• Research Institution: Kanazawa University
• Principal Investigator: SEKIYA Akiko 金沢大学, 保健学系, 助教 (10452111)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 不育症 / 妊娠 / 血栓 / ヘムオキシゲナーゼ-1 / スタチン

Outline of Final Research Achievements

The pathogenesis of recurrent miscarriage is poorly understood.
The blood coagulation-associated laboratory data of normal pregnant women demonstrated increased levels of thrombotic markers such as prothrombin fragment 1+2, thrombin-antithrombin complex, soluble fibrin and d-dimer. In BeWo cells, an in vitro model of the human placenta, TNF-α treatment enhanced expression of procoagulant proteins including tissue factor and plasminogen activator inhibitor-1 (PAI-1). Meanwhile, fluvastatin enhanced expression of anticoagulant proteins including tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin type 1 repeats (ADAMTS13) in human umbilical vein endothelial cells.
Those results indicate that pregnant women are at higher risk of thrombosis, which is accelerated by inflammation in some cases of adverse pregnancy outcome. Fluvastatin may improve antithrombotic properties of endothelium and attenuate thrombotic tendencies during pregnancy.

Free Research Field

血栓・止血学